SequelSEC

RenovoRx, Inc. RNXT

Pharmaceutical Preparations · CIK 0001574094 · Fiscal year ends 1231

Revenue
$1.12M
Fiscal year ended 2025-12-31
Operating income
-$12.51M
Fiscal year ended 2025-12-31
Free cash flow
-$10.98M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$26.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-06-30
Float per share$0.59Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue618.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity5.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth2511.6%98th
CapEx / revenue0.2%13th
FCF margin-977.3%24th
SBC / revenue112.8%70th
Net margin-994.5%31th
Operating margin-1114.0%32th
R&D / revenue558.2%67th
Current ratio4.02x53th
Gross margin70.9%48th

RenovoRx, Inc. (RNXT) reported revenue of $1.12M and net income of -$11.17M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from RenovoRx, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

RenovoRx, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$1.12M$43.00K
Cost of revenue$327.00K$0
Gross profit$796.00K$43.00K
Operating income-$12.51M-$10.97M
Net income-$11.17M-$8.81M
Research & development$6.27M$6.02M
Weighted-average diluted sharesshares 35.33Mshares 22.27M
Pretax income-$11.17M-$8.75M
Income tax expense$2.00KUnavailable
Diluted EPS$-0.32$-0.40
Selling, general & administrative$7.04M$4.99M
General & administrativeUnavailableUnavailable
Selling & marketingUnavailableUnavailable

Balance

RenovoRx, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$7.02M$7.15M
Total assets$8.10M$8.12M
Current assets$7.89M$7.83M
Total liabilities$2.67M$3.64M
Current liabilities$1.96M$1.91M
Total equity incl. NCI$5.42M$4.48M
Temporary (mezzanine) equityUnavailableUnavailable
Inventory$189.00K$0
Accounts receivable$139.00K$43.00K
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$799.00K$586.00K

Cash flow

RenovoRx, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$10.97M-$9.12M
Capital expenditures$2.00K$12.00K
Investing cash flow-$2.00K-$12.00K
Financing cash flow$10.84M$15.12M
Net change in cash-$130.00K$5.98M
Stock-based compensation$1.27M$1.17M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$2.00M$0

Derived

RenovoRx, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$10.98M-$9.14M
Gross margin70.9%100.0%
Operating margin-1114.0%-25511.6%
FCF margin-977.3%-21248.8%
SBC / revenue112.8%2730.2%
Current ratio4.02x4.10x
Revenue YoY growth2511.6%Unavailable
Net margin-994.5%-20497.7%
R&D / revenue558.2%14011.6%
CapEx / revenue0.2%27.9%
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RNXT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.